Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
Biologics are important treatment options for psoriasis; however, direct comparison of their efficacy, safety, and drug survival is insufficient in clinical practice. This retrospective single-center study aimed to compare the efficacy, safety, and drug survival of three commonly used psoriasis biol...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/5/1058 |
| _version_ | 1797501360734732288 |
|---|---|
| author | Seung-Won Jung Sung Ha Lim Jae Joon Jeon Yeon-Woo Heo Mi Soo Choi Seung-Phil Hong |
| author_facet | Seung-Won Jung Sung Ha Lim Jae Joon Jeon Yeon-Woo Heo Mi Soo Choi Seung-Phil Hong |
| author_sort | Seung-Won Jung |
| collection | DOAJ |
| description | Biologics are important treatment options for psoriasis; however, direct comparison of their efficacy, safety, and drug survival is insufficient in clinical practice. This retrospective single-center study aimed to compare the efficacy, safety, and drug survival of three commonly used psoriasis biologics (secukinumab, ustekinumab, and guselkumab) and identify the factors affecting drug survival in actual clinics in Korea. We enrolled 111 patients with moderate to severe psoriasis and for at least 56 weeks of follow-up; among these, 27, 23, and 61 were administered secukinumab, ustekinumab, and guselkumab, respectively. All groups were comparable with respect to their baseline characteristics. Secukinumab showed a rapid response, and guselkumab was superior in terms of a long-term response and complete remission compared with other biologics, while ustekinumab showed a lower efficacy compared with other biologics. All three biologics had a favorable and similar safety profile; however, allergic reactions and latent tuberculosis were more common with secukinumab and ustekinumab, respectively. Guselkumab was the most sustained biologic, and the survival rates of secukinumab and ustekinumab were similar. Drug survival was remarkably shorter in female patients and those with hypertension. Introduction of new biologics emerged as a negative factor for drug survival in clinical settings. |
| first_indexed | 2024-03-10T03:17:17Z |
| format | Article |
| id | doaj.art-31dcfc30c1794c79b211495ef5fd3ca0 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T03:17:17Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-31dcfc30c1794c79b211495ef5fd3ca02023-11-23T10:10:26ZengMDPI AGBiomedicines2227-90592022-05-01105105810.3390/biomedicines10051058Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean CenterSeung-Won Jung0Sung Ha Lim1Jae Joon Jeon2Yeon-Woo Heo3Mi Soo Choi4Seung-Phil Hong5Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju 26426, KoreaDepartment of Dermatology, Yonsei University Wonju College of Medicine, Wonju 26426, KoreaDepartment of Dermatology, Yonsei University Wonju College of Medicine, Wonju 26426, KoreaDepartment of Dermatology, Yonsei University Wonju College of Medicine, Wonju 26426, KoreaDepartment of Dermatology, Dankook University College of Medicine, Cheonan 31116, KoreaDepartment of Dermatology, Yonsei University Wonju College of Medicine, Wonju 26426, KoreaBiologics are important treatment options for psoriasis; however, direct comparison of their efficacy, safety, and drug survival is insufficient in clinical practice. This retrospective single-center study aimed to compare the efficacy, safety, and drug survival of three commonly used psoriasis biologics (secukinumab, ustekinumab, and guselkumab) and identify the factors affecting drug survival in actual clinics in Korea. We enrolled 111 patients with moderate to severe psoriasis and for at least 56 weeks of follow-up; among these, 27, 23, and 61 were administered secukinumab, ustekinumab, and guselkumab, respectively. All groups were comparable with respect to their baseline characteristics. Secukinumab showed a rapid response, and guselkumab was superior in terms of a long-term response and complete remission compared with other biologics, while ustekinumab showed a lower efficacy compared with other biologics. All three biologics had a favorable and similar safety profile; however, allergic reactions and latent tuberculosis were more common with secukinumab and ustekinumab, respectively. Guselkumab was the most sustained biologic, and the survival rates of secukinumab and ustekinumab were similar. Drug survival was remarkably shorter in female patients and those with hypertension. Introduction of new biologics emerged as a negative factor for drug survival in clinical settings.https://www.mdpi.com/2227-9059/10/5/1058psoriasisdirect comparison in real worldsecukinumabustekinumabguselkumab |
| spellingShingle | Seung-Won Jung Sung Ha Lim Jae Joon Jeon Yeon-Woo Heo Mi Soo Choi Seung-Phil Hong Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center Biomedicines psoriasis direct comparison in real world secukinumab ustekinumab guselkumab |
| title | Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center |
| title_full | Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center |
| title_fullStr | Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center |
| title_full_unstemmed | Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center |
| title_short | Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center |
| title_sort | comparison of the efficacy and safety of biologics secukinumab ustekinumab and guselkumab for the treatment of moderate to severe psoriasis real world data from a single korean center |
| topic | psoriasis direct comparison in real world secukinumab ustekinumab guselkumab |
| url | https://www.mdpi.com/2227-9059/10/5/1058 |
| work_keys_str_mv | AT seungwonjung comparisonoftheefficacyandsafetyofbiologicssecukinumabustekinumabandguselkumabforthetreatmentofmoderatetoseverepsoriasisrealworlddatafromasinglekoreancenter AT sunghalim comparisonoftheefficacyandsafetyofbiologicssecukinumabustekinumabandguselkumabforthetreatmentofmoderatetoseverepsoriasisrealworlddatafromasinglekoreancenter AT jaejoonjeon comparisonoftheefficacyandsafetyofbiologicssecukinumabustekinumabandguselkumabforthetreatmentofmoderatetoseverepsoriasisrealworlddatafromasinglekoreancenter AT yeonwooheo comparisonoftheefficacyandsafetyofbiologicssecukinumabustekinumabandguselkumabforthetreatmentofmoderatetoseverepsoriasisrealworlddatafromasinglekoreancenter AT misoochoi comparisonoftheefficacyandsafetyofbiologicssecukinumabustekinumabandguselkumabforthetreatmentofmoderatetoseverepsoriasisrealworlddatafromasinglekoreancenter AT seungphilhong comparisonoftheefficacyandsafetyofbiologicssecukinumabustekinumabandguselkumabforthetreatmentofmoderatetoseverepsoriasisrealworlddatafromasinglekoreancenter |